Atomoxetine in Patients With Tourette's Syndrome
Megadott ok: experimental treatment (Atomoxetine) not available
A legfontosabb adatok
- Fázis
- 2. fázis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- Poitiers University Hospital
- Azonosító
- NCT04354103
- A regiszteradat frissítve
- 2024. január 23.
- Eredeti leírás
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.A teljes eredeti leírásKevesebb
A Pilot Study to Evaluate the Effects of Atomoxetine on Impulsivity in Patients With Tourette's Syndrome
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.
Bevonási feltételek: High impulsive patients, aged 10-35 years old, diagnosed for Tourette's syndrome as defined by the DSM-IV, never treated by Atomoxetine; The use of effective contraception or abstinence for subjects of reproductive age; Written informed consent.
Kizáró feltételek: Patients with mental retardation, psychotic disorders as schizophrenia, autism spectrum disorders, chronic tics which do not respond to Tourette's syndrome criteria; Allergy to one of the constituents; Severe cardiovascular or cerebrovascular diseases, Pheochromocytoma, uncontrolled hyperthyroidism, closed angle glaucoma; Actual severe depression; IMAO treatment discontinued less than 2 months or contra-indicated associated treatment.